Michael Lohmüller

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Topics

High Throughput

Top Venues

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Katharina M C Klee, Michael W Hess, Michael Lohmüller, Sebastian Herzog, Kristian Pfaller, Thomas Müller, Georg-Friedrich Vogel, Lukas A Huber
A CRISPR screen in intestinal epithelial cells identifies novel factors for polarity and apical transport. eLife 12 (2023)
Katharina M C Klee, Michael W Hess, Michael Lohmüller, Sebastian Herzog, Kristian Pfaller, Thomas Müller, Georg-Friedrich Vogel, Lukas A Huber
A CRISPR screen in intestinal epithelial cells identifies novel factors for polarity and apical transport. eLife 12 (2023)
Katharina M C Klee, Michael W Hess, Michael Lohmüller, Sebastian Herzog, Kristian Pfaller, Thomas Müller, Georg-Friedrich Vogel, Lukas A Huber
A CRISPR screen in intestinal epithelial cells identifies novel factors for polarity and apical transport. eLife 12 (2023)
Katharina M C Klee, Michael W Hess, Michael Lohmüller, Sebastian Herzog, Kristian Pfaller, Thomas Müller, Georg-Friedrich Vogel, Lukas A Huber
A CRISPR screen in intestinal epithelial cells identifies novel factors for polarity and apical transport. eLife 12 (2023)
Katharina M C Klee, Michael W Hess, Michael Lohmüller, Sebastian Herzog, Kristian Pfaller, Thomas Müller, Georg-Friedrich Vogel, Lukas A Huber
A CRISPR-screen in intestinal epithelial cells identifies novel factors for polarity and apical transport. eLife 12 (2023)
Katharina M C Klee, Michael W Hess, Michael Lohmüller, Sebastian Herzog, Kristian Pfaller, Thomas Müller, Georg-Friedrich Vogel, Lukas A Huber
A CRISPR-screen in intestinal epithelial cells identifies novel factors for polarity and apical transport. eLife 12 (2023)
Michael Lohmüller, Bernhard F Roeck, Tamas G Szabo, Marina A Schapfl, Fragka Pegka, Sebastian Herzog, Andreas Villunger, Fabian Schuler
The SKP2-p27 axis defines susceptibility to cell death upon CHK1 inhibition. Molecular oncology 16 (15) (2022)
André Volland, Michael Lohmüller, Emmanuel Heilmann, Janine Kimpel, Sebastian Herzog, Dorothee von Laer
Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants. PLoS pathogens 17 (10) (2021)